Clinical trials: Neuroendocrine Tumors Unresectable
Melanoma
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: is advanced or metastatic (spread to other parts of…
- Trial name
- NCT04657991
- Testing
- Encorafenib, Binimetinib, Pembrolizumab
- Where
- 151 sites in United States, Argentina and 25 more
- Volunteers
- 257 people
- Sponsor
- Pfizer
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes…
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1
- Trial name
- NCT03375320
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 432 sites in United States
- Volunteers
- 298 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
This research study is a Phase II clinical trial of an investigational combination of drugs (vemurafenib and aldesleukin) to learn whether the combination works in treating a specific cancer.
- Trial name
- NCT01754376
- Testing
- Aldesleukin, Vemurafenib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Massachusetts General Hospital
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
The purpose of this study is to compare the clinical benefit, as measured by overall survival, of nivolumab with that of. dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma
- Trial name
- CheckMate 066 (NCT01721772)
- Testing
- BMS-936558 (Nivolumab), Dacarbazine
- Where
- 75 sites in Argentina, Australia and 14 more
- Volunteers
- 418 people
- Sponsor
- Bristol-Myers Squibb
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
Study of Ipilimumab in the Immune System
Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.
- Trial name
- NCT01715077
- Testing
- Ipilimumab at 3 mg/kg dose
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Cancer, Melanoma
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with…
- Trial name
- NCT00110994
- Testing
- Sorafenib (Nexavar, BAY43-9006), Dacarbazine
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Bayer
Melanoma
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
The purpose of the study is to demonstrate similar PK and efficacy and to show comparable safety and immunogenicity between JPB898, Opdivo-EU, and Opdivo-US, all administered in combination with Yervoy-EU (induction phase only)…
- Trial name
- NCT06587451
- Testing
- JPB898 (Induction and Maintenance), Opdivo-EU (Induction), Opdivo-US (Induction)
- Where
- 22 sites in Chile, Georgia and 9 more
- Volunteers
- 52 people
- Sponsor
- Sandoz
Melanoma
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma
- Trial name
- NCT02752074
- Testing
- pembrolizumab + epacadostat
- Where
- 129 sites in United States, Australia and 21 more
- Volunteers
- 706 people
- Sponsor
- Incyte Corporation
Melanoma
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an…
- Trial name
- NCT03199846
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Bristol-Myers Squibb
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery.
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
- Trial name
- NCT03891784
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
This phase Ib/II trial studies the best dose of glembatumumab vedotin when giving together with nivolumab and ipilimumab in treating patients with solid tumor that has spread to other places in the body and cannot be removed by…
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative, GPNMB Positive, HER2/Neu Negative
- Trial name
- NCT03326258
- Testing
- Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Malignant Skin Melanoma T0, Stage III Melanoma
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT…
- Conditions
- Malignant Skin Melanoma T0, Stage III Melanoma, Stage IV Melanoma, Amplification
- Trial name
- NILOMEL (NCT01168050)
- Testing
- Nilotinib
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Cancer, Melanoma (Skin)
ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 3521 in treating patients who have advanced…
- Trial name
- NCT00003989
- Testing
- ISIS 3521
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unresectable Malignant Neoplasm, Melanoma
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body.
- Conditions
- Unresectable Malignant Neoplasm, Melanoma, Metastatic Melanoma, Stage IV Melanoma
- Trial name
- NeoPembroMel (NCT02306850)
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- St. Louis University
Melanoma, Unresectable Melanoma
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma therapy.
- Conditions
- Melanoma, Unresectable Melanoma, Advanced Melanoma
- Trial name
- NCT03501368
- Testing
- Ceritinib, Trametinib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Unresectable Melanoma, Metastatic Melanoma
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
The objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.
- Trial name
- NCT05398640
- Testing
- OOS AMTAGVI
- Where
- 48 sites in United States
- Sponsor
- Iovance Biotherapeutics, Inc.
Neuroendocrine Tumors
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
This is an investigator-initiated research project aimed at exploring the efficacy and safety of Adebrelimab combined with chemotherapy and Apatinib as first-line treatment for unresectable locally advanced or metastatic…
- Trial name
- NCT06764368
- Testing
- Adebrelimab + Apatinib
- Volunteers
- 39 people
- Sponsor
- Beijing Chest Hospital